Zobrazeno 1 - 10
of 359
pro vyhledávání: '"Errol P, Prens"'
Autor:
Alexa B. Kimball, Errol P. Prens, Thierry Passeron, Emanual Maverakis, Irina Turchin, Stefan Beeck, Leonidas Drogaris, Ziqian Geng, Tianyu Zhan, Izabella Messina, Falk G. Bechara
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 5, Pp 1099-1111 (2023)
Abstract Introduction Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life. This study evaluated the efficacy and
Externí odkaz:
https://doaj.org/article/e2a729e34e50461897894ec721f0c23a
Autor:
Salma Assil, Thomas P. Buters, Pieter W. Hameeteman, Charlie Hallard, Nicoline Treijtel, Tessa Niemeyer – Van der Kolk, Marieke L. de Kam, Edwin F. I. I. I. Florencia, Errol P. Prens, Martijn B. A. van Doorn, Robert Rissmann, Naomi B. Klarenbeek, Manon A. A. Jansen, Matthijs Moerland
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Imiquimod (IMQ) is a topical agent that induces local inflammation via the Toll-like receptor 7 pathway. Recently, an IMQ-driven skin inflammation model was developed in healthy volunteers for proof-of-pharmacology trials. The aim of this study was t
Externí odkaz:
https://doaj.org/article/f03a8555dda44e0c8f9b4a37d47243ce
Autor:
Tessa Niemeyer‐van der Kolk, Hein van derWall, Geretta K. Hogendoorn, Rianne Rijneveld, Sascha Luijten, Dirk C.J.G. vanAlewijk, Ellen H.A. van denMunckhof, Marieke L. deKam, Gary L. Feiss, Errol P. Prens, Jacobus Burggraaf, Robert Rissmann, Martijn B.A. vanDoorn
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 5, Pp 994-1003 (2020)
Omiganan is an indolicidin analog with antimicrobial properties that could be beneficial for patients with atopic dermatitis. In this randomized, double‐blind, placebo‐controlled, phase II trial we explored the efficacy, pharmacodynamics, and saf
Externí odkaz:
https://doaj.org/article/a7ed2df291384c3c96ae015a342753ab
Autor:
Tessa Niemeyer‐van der Kolk, Salma Assil, Thomas P. Buters, Melanie Rijsbergen, Erica S. Klaassen, Gary Feiss, Edwin Florencia, Errol P. Prens, Jacobus Burggraaf, Martijn B.A. vanDoorn, Robert Rissmann, Matthijs Moerland
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 573-579 (2020)
Omiganan (OMN; a synthetic cationic peptide) and imiquimod (IMQ; a TLR7 agonist) have synergistic effects on interferon responses in vitro. The objective of this study was to translate this to a human model for proof‐of‐concept, and to explore th
Externí odkaz:
https://doaj.org/article/42391760444a4082ab3df6cc9a119ef1
Autor:
Pim Aarts, Johanna C. van Huijstee, Aviël Ragamin, Joanne L. Reeves, Catherine van Montfrans, Hessel H. van der Zee, Errol P. Prens
Publikováno v:
Dermatology, 239(1), 99-108. Karger
Background: After excision surgery in patients with hidradenitis suppurativa (HS), wounds are usually left open for secondary intention healing. To evaluate wound healing, reliable wound measurement is important. However, digital wound measurement to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c1eae3c268a86fa450483f9444ea004
https://doi.org/10.1159/000525844
https://doi.org/10.1159/000525844
Autor:
Johann E. Gudjonsson, Lam C. Tsoi, Feiyang Ma, Allison C. Billi, K.R. van Straalen, A.R.J.V. Vossen, H.H. van der Zee, Paul W. Harms, Rachael Wasikowski, Christine M. Yee, Syed M. Rizvi, Xianying Xing, Enze Xing, Olesya Plazyo, Chang Zeng, Matthew T. Patrick, Margaret M. Lowe, Richard E. Burney, Jeffrey H. Kozlow, Jill R. Cherry-Bukowiec, Yanyun Jiang, Joseph Kirma, Stephan Weidinger, Kelly C. Cushing, Michael D. Rosenblum, Celine Berthier, Amanda S. MacLeod, John J. Voorhees, Fei Wen, J. Michelle Kahlenberg, Emanual Maverakis, Robert L. Modlin, Errol P. Prens
Publikováno v:
JCI Insight, Vol 5, Iss 19 (2020)
Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by chronic abscess formation and development of multiple draining sinus tracts in the groin, axillae, and perineum. Using proteomic and transcriptomic app
Externí odkaz:
https://doaj.org/article/6a9a009215b84bf6a72948e92d18fa18
Autor:
Koen Dudink, Klasiena Bouwman, Yanqing Chen, Samuel E DePrimo, Ernesto J Munoz-Elias, Pim Aarts, Renske Schappin, Edwin F Florencia, Bennie van Heeswijk, Lisette M Prens, Hessel H van der Zee, Errol P Prens, Kelsey R van Straalen, Barbara Horváth
Publikováno v:
The British journal of dermatology, 188(5), 601-609. Wiley-Blackwell Publishing Ltd
Background The effectiveness of available biologics for the treatment of hidradenitis suppurativa (HS) is limited. Additional therapeutic options are needed. Objectives To investigate the efficacy and mode of action of guselkumab [an anti-interleukin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c4457f6eced82e3dbd65f4c82173954
https://pure.eur.nl/en/publications/b84d9b3c-e402-4832-8c4a-fdc9e1f2d91c
https://pure.eur.nl/en/publications/b84d9b3c-e402-4832-8c4a-fdc9e1f2d91c
Autor:
Pim Aarts, Johanna C. van Huijstee, Hessel H. van der Zee, Martijn B.A. van Doorn, Kelsey R. van Straalen, Errol P. Prens
Publikováno v:
Journal of the American Academy of Dermatology. Mosby Inc.
Background: Adalimumab, the only biologic registered for hidradenitis suppurativa, shows clinical response in up to 60% of patients, leaving many patients in need for other treatment options such as surgery. Objective: To compare the clinical effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa3748b5f46c5d74547da2585ed87a3
https://pure.eur.nl/en/publications/4d474663-6a7c-4e52-bfd1-81b2039c8a90
https://pure.eur.nl/en/publications/4d474663-6a7c-4e52-bfd1-81b2039c8a90
Publikováno v:
Dermatology.
Background: Antibiotic resistance is a major concern, especially in HS. However, antibiotics form a cornerstone in its treatment. Topical clindamycin is known to cause bacterial resistance, but is still advised as monotherapy for the treatment of mil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5214e8489b7d077dfa9f4e62d4a24c17
https://doi.org/10.1159/000530758
https://doi.org/10.1159/000530758
Autor:
Wouter ten Voorde, Mahdi Saghari, Jiry Boltjes, Marieke L. de Kam, Ahnjili Zhuparris, Gary Feiss, Thomas P. Buters, Errol P. Prens, Jeffrey Damman, Tessa Niemeyer‐van der Kolk, Matthijs Moerland, Jacobus Burggraaf, Martijn B. A. van Doorn, Robert Rissmann
Publikováno v:
Experimental Dermatology. Wiley-Blackwell Publishing Ltd
Experimental Dermatology
Experimental Dermatology
Development of pharmacological interventions for wound treatment is challenging due to both poorly understood wound healing mechanisms and heterogeneous patient populations. A standardized and well-characterized wound healing model in healthy volunte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186f9c83f8f091954098ce099f154e73
https://pure.eur.nl/en/publications/85f5792e-7116-4dbc-a21f-346ecc6a53c1
https://pure.eur.nl/en/publications/85f5792e-7116-4dbc-a21f-346ecc6a53c1